Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-CD19 monoclonal antibody and preparation method thereof

An antibody and CDR2 technology, applied in the field of biomedicine, can solve the problems of unsatisfactory performance of CD19 protein antibody

Active Publication Date: 2016-08-10
PERSONGEN ANKE CELLULAR THERAPEUTICS CO LTD
View PDF3 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the performance of the current antibodies against CD19 protein is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CD19 monoclonal antibody and preparation method thereof
  • Anti-CD19 monoclonal antibody and preparation method thereof
  • Anti-CD19 monoclonal antibody and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0151] Preparation of monoclonal antibodies

[0152] Antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, an antigen of the invention may be administered to an animal to induce the production of monoclonal antibodies. For monoclonal antibodies, hybridoma technology can be used to prepare (see Kohler et al., Nature 256; 495, 1975; Kohler et al., Eur.J.Immunol.6:511, 1976; Kohler et al., Eur.J.Immunol. 6:292,1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981) or can be prepared by recombinant DNA method (US Patent No. 4,816,567).

[0153] Representative myeloma cells are those that fuse efficiently, support stable high-level production of antibody by selected antibody-producing cells, and are sensitive to culture medium (HAT medium matrix), including myeloma cell lines, such as murine Myeloma cell lines, including those derived from MOPC-21 and MPC-11 mouse tumors (a...

Embodiment 1

[0184] Step 1: Preparation of hybridoma cells

[0185]Immune female healthy BALB / c mice with B cell line tumor cells or CD19 eukaryotic recombinant protein antigen, select the mice with positive serum ELISA, WB, FC, extract spleen cells from them, and fuse with myeloma cells , forming hybridoma cells; hybridoma cells were cultured in HAT medium, and the monoclonal cells that were positive in high-throughput flow cytometry screening were re-screened by ELISA to obtain 36 positive clones, and then re-screened by WB to obtain positive clones 9 strains were subcloned to WB-positive cells. After 2 times of subcloning, 6 strains of negative cell strains during the subcloning process were excluded, and finally 3 strains of monoclonal cells capable of stably secreting CD19 antibodies were selected (including: PGC3D6H10 monoclonal antibody cell line, PGA6E2D5 monoclonal antibody cell line, PGA6D5C6 monoclonal antibody cell line); use the subtype identification kit to identify the subty...

Embodiment 2

[0199] Cloning of Example 2 Anti-CD19 Monoclonal Antibody Heavy Chain and Light Chain Variable Region Genes

[0200] The cell line used is a hybridoma cell line that can secrete high-affinity and high-specificity anti-CD19 monoclonal antibody obtained by the above method, the corresponding number is PGC3D6H10, and the corresponding antibody molecular subtypes are: heavy chain IgG1 type, light Chain kappa type.

[0201] Take hybridoma cells in logarithmic growth phase 2×10 6 , Tri zol method to extract total cellular RNA,

[0202] A small amount was quantified by Nanodrop and detected by 1% non-denaturing agarose gel electrophoresis, then the cDNA was reverse-transcribed with SuperScript.I II First-Strand Synthesis System for RT-PCR kit (K1622, Thermo), and the specific primer was used to amplify the anti- The heavy or light chain variable region of the CD19 antibody gene. The PCR reaction product containing the corresponding heavy chain variable region or light chain variab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides an anti-CD19 monoclonal antibody, and a preparation method and an application thereof. The anti-CD19 monoclonal antibody can effectively recognize cells with CD19 highly expressed, and can be successfully used for Western Blot detection. An affinity test shows that the monoclonal antibody has the extremely high affinity to target protein.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular, the invention relates to an anti-CD19 monoclonal antibody and a preparation method thereof. Background technique [0002] CD19 is expressed in both normal and malignant B lymphocytes, and is regarded as the most reliable surface marker covering a long period of B cell development. In normal lymphoid tissue, CD19 is expressed in B cells in the germinal center and dendritic cells in the follicular dendritic cells, mantle cells, and dendritic cells in the interfollicular T cell zone. In fact, the CD19 molecule is mainly expressed in early B cells, and it is a transmembrane glycoprotein unique to B cell lines of about 95KDa. [0003] As a cell surface molecule expressed by B cells during their differentiation and proliferation. CD19 is generally considered a therapeutic target for the treatment of B-cell disorders or diseases such as B-cell malignancies, autoimmune diseases, and transplant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/30C12N15/13C12N15/63C12N5/10A61K47/48A61K39/395A61P35/00C12P21/00
CPCA61K39/395C07K16/30C12P21/00
Inventor 杨林陈丹邹建炫
Owner PERSONGEN ANKE CELLULAR THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com